Gapping up
In reaction to earnings/guidance:
- SFIX +14.3%, DADA +10.8% (also announces $150 mln share repurchase plan), REVG +8%, MRVL +5.6%, THO +5.1%, NAPA +3%, LUV +1.2%, WWW +0.9% (guides Q2 revs above pre-pandemic levels)
Other news:
- SLQT +11.5% (to join S&P SmallCap 600)
- MCF +9.3% (Contango Oil & Gas and Independence Energy to combine in all-stock merger)
- ATCX +7.2% (files for $250 mln mixed securities shelf offering; also files for 29,678,938 offering by selling shareholders)
- CHS +6.1% (issues statement in response to letter issued by Barington Group)
- VCNX +5% (plans to activate at least 13 clinical sites for Alzheimer's study and 18 clinical sites for head and neck cancer across the US)
- CW +4% (awarded contract by LMT worth up to $70 mln)
- JWEL +3.8% (signs strategic cooperation agreement for COCOVEL brand with Shanghai Gesber Group to jointly seek household product business growth)
- TLRY +3.4% (announces launch of new medical cannabis brand, Symbios)
- TSLA +3.1% (discloses departure of Jerome Guillen, President, Tesla Heavy Trucking)
- HOOK +3.1% (provides Phase 1 HB-200 data)
- AFYA +3.1% (notified of stake purchase by Bertelsmann affiliate)
- CAMT +2.7% (received orders for inspection and metrology systems totaling about $60 mln since the beginning of April; expected to be delivered primarily during the second half of 2021)
- PLTR +1.6% (receives $7.4 mln one-year contract renewal with the CDC)
- MRNA +1.2% (New CDC study finds that mRNA COVID-19 vaccines reduce risk of infection by 91% for fully vaccinated people)
Analyst comments:
- JCI +2.6% (upgraded to Overweight from Neutral at JP Morgan)
- ARCB +2% (upgraded to Buy from Hold at Vertical Research)
- ARES +1.7% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- DAL +1.7% (upgraded to Buy from Hold at Jefferies)
- GNRC +1.5% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- LDOS +1.5% (upgraded to Conviction Buy from Buy at Goldman)
- LW +1.4% (upgraded to Buy from Hold at Jefferies)